We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher Poised on Innovation, Global Growth Amid Woes
Read MoreHide Full Article
On Mar 16, 2017, we issued an updated research report on Thermo Fisher Scientific Inc. (TMO - Free Report) , a scientific instrument maker and world leader in serving science. Over the past three months, Thermo Fisher has traded above the Zacks categorized Medical - Instruments industry.
The market was concerned about Thermo Fishers’ sluggish top-line performance in the last reported fourth-quarter 2016, which was affected by four less selling days in the quarter. But the company’s recent product launches and strong emerging market growth buoy optimism.
Additionally, we are encouraged by Thermo Fishers’ strong bottom-line performance and a solid guidance that raised the stock price. Also, we believe Thermo Fishers’ colossal $4.2 billion acquisition of FEI Company is going to significantly facilitate the company’s performance in life-science research.
Moreover, the integration and expected synergy of Affimetrix, another mega acquisition of Thermo Fisher, are anticipated to boost its offering in the fast-growing flow cytometry market. Per the last trading price, the stock increased 11.87% over the past three months, ahead of the broader market’s gain of 10.99%.
This apart, Thermo Fisher boasts strong international operations and has witnessed consistent growth in the Asia-Pacific and emerging markets. The company plans to continue strengthening its foothold in emerging markets, such as China and India, and also translate this success to other high-priority opportunities in regions such as South Korea, Russia and Brazil.
On the flip side, flat organic top-line growth during the last-reported quarter was disappointing. Even for the year 2017, the company forecasted organic growth of just 4%. This prediction was due to an expectation that it might register a growth below 4% in the first quarter, on the basis of certain spending restriction, thereby indicating gloomy scenario ahead.
Also currency headwinds continue to act as major dampener. In 2016, the company’s earnings were affected to the tune of 2.5% on headwind from foreign exchange. In addition, the company currently estimates an unfavorable foreign exchange to have a negative impact on its top-line performance even in 2017. Further, it has also forecasted foreign exchange to affect revenues by $300 million in 2017, which in turn might impact of over 1.5%.
Zacks Rank & Key Picks
Thermo Fisher currently has a Zacks Rank #3 (Hold). Better-ranked stocks in the medical product sector are Inogen, Inc. (INGN - Free Report) , Bovie Medical Corp. and ResMed, Inc. (RMD - Free Report) . While Inogen sports a Zacks Rank #1 (Strong Buy), the other two companies carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen gained 87.3% in the last year in comparison with the S&P 500’s return of 16.8%. The company has a stellar four-quarter average earnings surprise of over 49.08%.
Bovie Medical surged 44.7% in the last one year in comparison with the S&P 500. It has a four-quarter average earnings surprise of 28.7%.
ResMed gained over 27.7% in the past one year, better than the S&P 500 mark. It also has a trailing average earnings surprise of 0.31%.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Thermo Fisher Poised on Innovation, Global Growth Amid Woes
On Mar 16, 2017, we issued an updated research report on Thermo Fisher Scientific Inc. (TMO - Free Report) , a scientific instrument maker and world leader in serving science. Over the past three months, Thermo Fisher has traded above the Zacks categorized Medical - Instruments industry.
The market was concerned about Thermo Fishers’ sluggish top-line performance in the last reported fourth-quarter 2016, which was affected by four less selling days in the quarter. But the company’s recent product launches and strong emerging market growth buoy optimism.
Additionally, we are encouraged by Thermo Fishers’ strong bottom-line performance and a solid guidance that raised the stock price. Also, we believe Thermo Fishers’ colossal $4.2 billion acquisition of FEI Company is going to significantly facilitate the company’s performance in life-science research.
Moreover, the integration and expected synergy of Affimetrix, another mega acquisition of Thermo Fisher, are anticipated to boost its offering in the fast-growing flow cytometry market. Per the last trading price, the stock increased 11.87% over the past three months, ahead of the broader market’s gain of 10.99%.
Thermo Fisher Scientific Inc Price
Thermo Fisher Scientific Inc Price | Thermo Fisher Scientific Inc Quote
This apart, Thermo Fisher boasts strong international operations and has witnessed consistent growth in the Asia-Pacific and emerging markets. The company plans to continue strengthening its foothold in emerging markets, such as China and India, and also translate this success to other high-priority opportunities in regions such as South Korea, Russia and Brazil.
On the flip side, flat organic top-line growth during the last-reported quarter was disappointing. Even for the year 2017, the company forecasted organic growth of just 4%. This prediction was due to an expectation that it might register a growth below 4% in the first quarter, on the basis of certain spending restriction, thereby indicating gloomy scenario ahead.
Also currency headwinds continue to act as major dampener. In 2016, the company’s earnings were affected to the tune of 2.5% on headwind from foreign exchange. In addition, the company currently estimates an unfavorable foreign exchange to have a negative impact on its top-line performance even in 2017. Further, it has also forecasted foreign exchange to affect revenues by $300 million in 2017, which in turn might impact of over 1.5%.
Zacks Rank & Key Picks
Thermo Fisher currently has a Zacks Rank #3 (Hold). Better-ranked stocks in the medical product sector are Inogen, Inc. (INGN - Free Report) , Bovie Medical Corp. and ResMed, Inc. (RMD - Free Report) . While Inogen sports a Zacks Rank #1 (Strong Buy), the other two companies carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen gained 87.3% in the last year in comparison with the S&P 500’s return of 16.8%. The company has a stellar four-quarter average earnings surprise of over 49.08%.
Bovie Medical surged 44.7% in the last one year in comparison with the S&P 500. It has a four-quarter average earnings surprise of 28.7%.
ResMed gained over 27.7% in the past one year, better than the S&P 500 mark. It also has a trailing average earnings surprise of 0.31%.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>